‘Pulmonary arterial hypertension can cause dyspnoea on exertion and leads to right heart failure. It can be idiopathic and familial or can be associated with connective tissue diseases and congenital heart disease with repaired shunts.
The available treatments for pulmonary arterial hypertension include calcium channel blockers, endothelin antagonists, phosphodiesterase 5 inhibitors and prostacyclins. Some patients require combinations of these drugs and some will not respond and will need a lung transplant. Macitentan is a drug approved for pulmonary arterial hypertension . It is known as Opsumit (Actelion) and is available as 3 mg and 10 mg film-coated tablets .’
The enclosed article from the Australian Prescriber provides detailed information regarding this drug.